In 2025, Fundsmith Equity Fund began building a position in Zoetis, while the company reported third-quarter revenue growth and addressed safety concerns surrounding its Librela osteoarthritis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback